Predicted to enable dynein heavy chain binding activity and dynein light chain binding activity. Predicted to contribute to plus-end-directed microtubule motor activity. Involved in brain development; cellular response to nerve growth factor stimulus; and negative regulation of neuron projection development. Located in cytoplasm. Orthologous to human DYNC1I2 (dynein cytoplasmic 1 intermediate chain 2); PARTICIPATES IN mitochondria transport pathway; phagocytosis pathway; vasopressin signaling pathway via receptor type 2; INTERACTS WITH 2,3,7,8-tetrachlorodibenzodioxine; 2,4-dibromophenyl 2,4,5-tribromophenyl ether; 2,6-dinitrotoluene.
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of DYNC1I2 mRNA
[Acrolein co-treated with methacrylaldehyde co-treated with alpha-pinene co-treated with Ozone] results in increased oxidation of DYNC1I2 mRNA, [Air Pollutants results in increased abundance of [Acrolein co-treated with methacrylaldehyde co-treated with alpha-pinene co-treated with Ozone]] which results in increased oxidation of DYNC1I2 mRNA
[Acrolein co-treated with methacrylaldehyde co-treated with alpha-pinene co-treated with Ozone] results in increased oxidation of DYNC1I2 mRNA, [Air Pollutants results in increased abundance of [Acrolein co-treated with methacrylaldehyde co-treated with alpha-pinene co-treated with Ozone]] which results in increased oxidation of DYNC1I2 mRNA
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of DYNC1I2 mRNA
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of DYNC1I2 mRNA
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of DYNC1I2 mRNA
[Acrolein co-treated with methacrylaldehyde co-treated with alpha-pinene co-treated with Ozone] results in increased oxidation of DYNC1I2 mRNA more ...
[sodium arsenite co-treated with sodium arsenite deficiency] results in decreased methylation of DYNC1I2 promoter, [sodium arsenite co-treated with sodium arsenite deficiency] results in increased expression of DYNC1I2 mRNA
Live cell imaging reveals differential modifications to cytoplasmic dynein properties by phospho- and dephosphomimic mutations of the intermediate chain 2C S84.